S-1/A: CNS Pharmaceuticals Announces Public Offering of Common Stock and Warrants to Fund Glioblastoma Trial

CNS Pharmaceuticals is undertaking a public offering to raise capital for its CNS-201 trial, other research and development, and working capital.

Summary

• CNS Pharmaceuticals is offering up to 8,771,930 shares of common stock, pre-funded warrants for up to 8,771,930 shares, Series F warrants for up to 8,771,930 shares, and Series G warrants for up to 8,771,930 shares.
• The assumed combined public offering price is $1.14 per share and accompanying common warrants, with the common warrants having an assumed exercise price of $1.14 per share.
• The Series F warrants expire five years from the Initial Exercise Date or the Warrant Stockholder Approval, as applicable, and the Series G warrants expire 18 months from the Initial Exercise Date or the Warrant Stockholder Approval, as applicable.
• Pre-funded warrants are offered to investors whose purchase would result in exceeding 4.99% (or 9.99%) ownership, with an exercise price of $0.001 per share and a combined purchase price of $5.349 per pre-funded warrant and accompanying common warrants.
• The offering is on a reasonable best efforts basis, with A.G.P./Alliance Global Partners as lead placement agent and Brookline Capital Markets as co-placement agent.
• The company intends to use the net proceeds primarily to fund its CNS-201 trial, other research and development, and for working capital.
• The offering is expected to close on or about [__________], 2024, subject to customary closing conditions.
• The company may amend outstanding Series A and Series B common warrants to reduce the exercise price and extend the term to match the new warrants.

Sentiment

Score: 4

Explanation: The announcement is largely negative due to the dilution, the company's financial situation, and the risks associated with the offering. The company needs the capital to continue operations, but the terms are not favorable for new investors.

Positives

• The offering will provide capital to fund the CNS-201 trial, which is a potentially pivotal trial for Berubicin.
• The company has the flexibility to use proceeds for other research and development activities.
• The offering includes pre-funded warrants, which may be attractive to certain investors.
• The company may amend existing warrants to make them more attractive to investors.

Negatives

• The offering is on a best efforts basis, so there is no guarantee that the company will raise the full amount of capital it is seeking.
• The company will incur dilution as a result of issuing new shares and warrants.
• There is no established public trading market for the warrants.
• The warrants may not be exercisable if the company is required to obtain Warrant Stockholder Approval and is unable to do so.

Risks

• The results of the interim analysis of the CNS-201 trial may not be indicative of the final results.
• The company is not in compliance with Nasdaq's continued listing requirements, and delisting could have a material adverse effect.
• The company has broad discretion in how it uses the proceeds of this offering and may not use these proceeds effectively.
• The company will require substantial funding, which may not be available on acceptable terms, or at all.
• Purchasers in this offering will experience immediate and substantial dilution in net tangible book value.
• There is no public market for the common warrants or pre-funded warrants being offered in this offering.
• If the company is required to obtain Warrant Stockholder Approval, until it is able to receive such approval the common warrants will not be exercisable, and if it is unable to obtain such approval the common warrants will have no value.
• Holders of the company's common warrants and pre-funded warrants will have no rights as a common stockholder until they acquire the company's common stock.
• If the company does not maintain a current and effective prospectus relating to the common stock issuable upon exercise of the common warrants and pre-funded warrants, public holders will only be able to exercise such common warrants and pre-funded warrants on a cashless basis.
• The common warrants and pre-funded warrants are speculative in nature.
• This is a best efforts offering.
• The company may be required to repurchase the common warrants, which may prevent or deter a third party from acquiring the company.
• If the company's stock price fluctuates after the offering, you could lose a significant part of your investment.
• This offering may cause the trading price of the company's common stock to decrease.
• The company has never paid dividends on its capital stock, and it does not anticipate paying dividends in the foreseeable future.

Future Outlook

The company intends to use the net proceeds from this offering primarily to fund its CNS-201 trial, other research and development, and for working capital. The company believes that its existing cash and cash equivalents plus the proceeds from this offering (assuming it completes the maximum offering of which there is no assurance) will be sufficient to meet its projected operating requirements into the second quarter of 2025.

Industry Context

The company is focused on developing anti-cancer drug candidates for the treatment of brain and central nervous system tumors, specifically Glioblastoma Multiforme. The company believes its lead drug candidate, Berubicin, may be a significant development in the treatment of Glioblastoma and other CNS malignancies, and if approved by the U.S. Food and Drug Administration (FDA), could give Glioblastoma patients an important new therapeutic alternative to the current standard of care.

Stakeholder Impact

• Existing shareholders will experience dilution.
• New investors face the risk of losing a significant portion of their investment.
• The company's ability to continue operations depends on the success of the offering.
• The company's employees and other stakeholders are affected by the company's financial condition.

Next Steps

• The company will seek to close the offering and use the proceeds to fund its CNS-201 trial, other research and development, and for working capital.
• The company may seek to amend outstanding Series A and Series B common warrants to reduce the exercise price and extend the term to match the new warrants.
• The company will need to regain compliance with Nasdaq's continued listing requirements.

Key Dates

Keywords

public offering, common stock, warrants, pre-funded warrants, CNS Pharmaceuticals, Berubicin, glioblastoma, CNS-201 trial, A.G.P./Alliance Global Partners, Brookline Capital Markets, securities, financing